Fosun Pharma Weekly Report | Deepening Global Collaborations: Hansizhuang Achieves New Milestones in International Commercialization

Fosun Wanbang Pharma Group andJunshi BiosciencesReached R&D and Commercialization Collaboration on Xuekaoqibaimab (IL-17A)

Fosun Pharmaceutical(Stock Codes: 600196.SH; 02196.HK) Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (“Fosun Wanbang”), a controlled subsidiary, and Junshi Biosciences (Stock Codes: 688180.SH, 01877.HK) recently signed a licensing agreement, reaching a collaboration on the development, registration, manufacturing, and commercialization of rocapitibart (JS005, an anti-IL-17A monoclonal antibody) in the Greater China region (Mainland China, Hong Kong, Macao, and Taiwan).

Nokocibart has completed its Phase III registrational clinical study in China among adult patients with moderate-to-severe plaque psoriasis, demonstrating excellent efficacy and safety. In the 150 mg dose group, the PASI 90 response rate reached 91% at Week 16, and the PASI 100 response rate reached 65% at Week 52. In December 2025, the New Drug Application (NDA) for nokocibart for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy was accepted by the National Medical Products Administration (NMPA). Currently, all participants in the Phase II clinical trial of nokocibart for the treatment of active ankylosing spondylitis (AS) have completed study follow-up.

Fosun Pharmaceutical’s Subsidiary Henlius’ Serplulimab Approved by South Korea’s MFDS for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

On July 2, Shanghai Henlius Biotech, Inc. (HKEX Stock Code: 2696) and Alvogen Korea Co., Ltd., a wholly-owned subsidiary of Lotus Pharmaceutical Co., Ltd. (TWSE Stock Code: 1795), jointly announced that SERPLUMA® (generic name: serplulimab; Chinese brand name: Hansizhuang®), a humanized anti-PD-1 monoclonal antibody independently developed by Henlius, has received approval from the Ministry of Food and Drug Safety (MFDS) of South Korea. It is approved for use in combination with carboplatin and etoposide as first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC), providing a new immuno-oncology treatment option for patients in South Korea.

Hansizhuang® has been recommended by the UK's NICE and officially included in the NHS reimbursement system, becoming the first anti-PD-1 immunotherapy drug for the treatment of extensive-stage small cell lung cancer within the NHS in England and Wales.

Recently, Henlius, a subsidiary of Fosun Pharmaceutical, and Accord Healthcare UK announced that H Drug, Hansizhuang® (serplulimab; European brand name: Hetronifly®), has been recommended by the UK National Institute for Health and Care Excellence (NICE) for formal inclusion in the routine clinical use scope of the National Health Service (NHS) in England and Wales.

Akonze® DESCEND Study Prominently Published in JCO, Reshaping the New Landscape of CINV Management in the Immunotherapy Era!

Netupitant/Palonosetron Capsules (Brand Name: Akynzeo®): The DESCEND Study (a nationwide, multicenter, investigator-initiated trial [IIT]) has been successfully published in the Journal of Clinical Oncology (Impact Factor: 43.4) due to its significant findings in the management of chemotherapy-induced nausea and vomiting (CINV). Addressing the critical clinical need for optimizing antiemetic regimens for highly emetogenic chemotherapy in the era of immunotherapy, this study provides a novel antiemetic option that balances efficacy with the requirements of immunotherapy.

Sisram Medical Technologies’ China Production Base Officially Commences Operations; First Domestically Produced Energy-Based Device, Alma Rejuve, Successfully Rolls Off the Production Line

On June 29, Sisram Medical Ltd. (“Sisram”; Stock Code: 1696.HK) announced that its production base in Miyun, Beijing, had been officially completed and put into operation, with the first China-produced energy-based device, Alma Rejuve, successfully rolling off the production line simultaneously. The official commencement of operations at this facility represents a significant step in optimizing the company’s global intelligent manufacturing layout, implementing Israel’s mature manufacturing system in China and completing its iterative upgrade. This milestone marks the entry of the company’s localized production strategy into a new phase of substantive operational implementation.

Contact Information

Media:pr@fosunpharma.com

Investors:ir@fosunpharma.com